View by Specialty

Trending

AdobeStock_Carrots_1200x630
November 18, 2024
1 min read
Save

CDC: 1 dead in multistate outbreak of E. coli linked to organic carrots

Neurocritical Care News

SPONSORED CONTENT
Save
SPONSORED CONTENT
July 18, 2024
1 min read
Save

Antidopaminergics linked to worse cognitive, functional outcomes in HD at 6 years

Antidopaminergics linked to worse cognitive, functional outcomes in HD at 6 years

Antidopaminergic medications were linked to worsening cognitive and functional effects that accelerate disease progression in Huntington’s disease, according to research presented at the Congress of the European Academy of Neurology.

SPONSORED CONTENT
July 17, 2024
1 min read
Save

FDA grants RMAT designation for stiff person syndrome therapy

FDA grants RMAT designation for stiff person syndrome therapy

The FDA has granted Regenerative Medicine Advanced Therapy designation to a Bay Area-based biopharmaceutical company for its autologous, fully human CD19 chimeric antigen receptor to treat those with refractory stiff person syndrome.

Trending

AdobeStock_Carrots_1200x630
November 18, 2024
1 min read
Save

CDC: 1 dead in multistate outbreak of E. coli linked to organic carrots

SPONSORED CONTENT
July 17, 2024
1 min read
Save

NYU Langone tops list again as best US hospital for neurology, neurosurgery

NYU Langone tops list again as best US hospital for neurology, neurosurgery

NYU Langone was again the top hospital in the United States for neurology and neurosurgery, according to the latest annual Best Hospitals Survey issued by U.S. News & World Report.

SPONSORED CONTENT
July 16, 2024
1 min read
Save

Initial testing promising for hemostatic hydrogel to treat TBI

Initial testing promising for hemostatic hydrogel to treat TBI

A Brooklyn-based biotech firm has announced successful completion of the first phase of a preclinical study conducted with the Walter Reed Army Institute of Research involving a proprietary hemostatic hydrogel to treat traumatic brain injury.

SPONSORED CONTENT
July 16, 2024
2 min read
Save

Ketamine may be better option than ECT for less severe treatment-resistant depression

Ketamine may be better option than ECT for less severe treatment-resistant depression

Individuals with moderate to less severe treatment-resistant depression may benefit from treatment with ketamine instead of electroconvulsive therapy, according to research from JAMA Network Open.

SPONSORED CONTENT
July 11, 2024
2 min read
Save

No significant difference in clinical outcomes, recovery in college athletes with concussion

No significant difference in clinical outcomes, recovery in college athletes with concussion

No significant differences were found in clinical outcomes or recovery time in college athletes who returned to play following concussion compared with those immediately removed, according to research from Neurosurgical Focus.

SPONSORED CONTENT
July 11, 2024
1 min read
Save

Disease progression slowed by 80% at 24 months in phase 1/2 studies of HD gene therapy

Disease progression slowed by 80% at 24 months in phase 1/2 studies of HD gene therapy

Interim results of phase 1/2 clinical trials of an investigational gene therapy for Huntington’s disease showed that disease progression slowed by 80% at 24 months, according to the manufacturer.

SPONSORED CONTENT
July 10, 2024
2 min read
Save

Brain stimulation may have distinct near-maximal effective doses across mental disorders

Brain stimulation may have distinct near-maximal effective doses across mental disorders

Significant dose-response associations were found for transcranial magnetic stimulation and transcranial direct current stimulation across several mental disorders, including schizophrenia and depression, according to research.

SPONSORED CONTENT
July 10, 2024
1 min read
Save

Interim phase 1/2a study results positive for investigational Parkinson’s cell therapy

Interim phase 1/2a study results positive for investigational Parkinson’s cell therapy

A South Korean biomedical company has announced positive 1-year assessment data from a phase 1/2a clinical trial of a human embryonic stem cell-derived midbrain dopaminergic progenitor for Parkinson’s disease.

SPONSORED CONTENT
July 09, 2024
1 min read
Save

Subcutaneous combination therapy improves ‘good on’ time in Parkinson’s

Subcutaneous combination therapy improves ‘good on’ time in Parkinson’s

Treatment with an investigational subcutaneous combination therapy for Parkinson’s disease improved ‘good on’ time by almost 2 hours per day, was safe and efficacious with treatment effect similar across a range of subgroups.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails